Wallentin L

Vascular endothelial growth factor-D plasma levels and VEGFD genetic variants are independently associated with outcomes in patients with cardiovascular disease.

Davidsson P, Eketjäll S, Eriksson N, ..., White H, Wallentin L

Cardiovasc. Res. 119 (7) 1596-1605 [2023-07-04; online 2023-03-05]

Affinity Proteomics Uppsala [Service] NGI SNP genotyping [Service] NGI Uppsala (SNP&SEQ Technology Platform) [Service] National Genomics Infrastructure [Service]

Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.

Pol T, Hijazi Z, Lindbäck J, ..., Siegbahn A, Wallentin L

Cardiovasc. Res. 118 (9) 2112-2123 [2022-07-20; online 2021-08-07]

Affinity Proteomics Uppsala [Service]

Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality.

Schunk SJ, Kleber ME, März W, ..., eQTLGen consortium , BIOS consortium

Eur. Heart J. 42 (18) 1742-1756 [2021-05-07; online 2021-03-23]

NGI Uppsala (SNP&SEQ Technology Platform) [Service] National Genomics Infrastructure [Service]

Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study.

Wallentin L, Eriksson N, Olszowka M, ..., Åberg M, Siegbahn A

PLoS Med. 18 (1) e1003513 [2021-01-00; online 2021-01-13]

Affinity Proteomics Uppsala [Service]

Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.

Wallentin L, Lindbäck J, Eriksson N, ..., Oldgren J, Siegbahn A

Eur. Heart J. 41 (41) 4037-4046 [2020-11-01; online 2020-09-29]

Affinity Proteomics Uppsala [Service] NGI Uppsala (SNP&SEQ Technology Platform) [Service] National Genomics Infrastructure [Service]